TrialLung cancer (Amsterdam, Netherlands)2023

Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study.

Matthew G Krebs et al.PubMed ↗Publisher ↗

No numbers read from the abstract.